Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Jeanette Doorduijn, MD, PhD

Erasmus MC Cancer Institute, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON /LLPC, Netherlands

N/A

Poster(s):

3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)